Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2003 Mar;16(3):202-6.
doi: 10.1007/s00147-002-0487-9. Epub 2003 Feb 13.

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

Valter Duro Garcia  1 , José Luz Bonamigo Filho, Jorge Neumann, Laura Fogliatto, Anna Maria Geiger, Clotilde Druck Garcia, Vivianne Barros, Elizete Keitel, Antonio Eduardo Bittar, Auri Ferrera des Santos, Sergio Roithmann
Affiliations
Case Reports

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

Valter Duro Garcia et al. Transpl Int. 2003 Mar.

Abstract

Post-transplant lymphoproliferative disease (PTLD) is an uncommon but life-threatening complication of solid-organ and blood stem-cell transplants. It responds poorly to therapy, including reduction of immunosuppression, interferon, antivirals or chemotherapy. Small series of PTLD successfully treated with rituximab have been reported, and experimental studies suggest that rapamycin inhibits growth of human Epstein-Barr virus-transformed B lymphocytes. We report two cases of PTLD after renal transplantation that were successfully treated with rituximab in association with rapamycin. This report suggests that rituximab associated with rapamycin could be an effective and safe treatment for PTLD.

PubMed Disclaimer

Publication types

LinkOut - more resources